Researchers provide molecular portraits of a new cancer drug target

December 19, 2016, University of Minnesota

Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.

The research is published today online in Nature Structural and Molecular Biology.

The DNA mutating enzymes called APOBECs are a major source of mutation in breast, lung, cervical, head/neck and many other cancer types.

"These enzymes normally function to protect us from viral infections," said Reuben Harris, Ph.D., investigator of the Howard Hughes Medical Institute and professor of Biochemistry, Molecular Biology, and Biophysics, member of the Masonic Cancer Center, and associate director of the Institute of Molecular Virology, University of Minnesota. "However, these enzymes can become misregulated in cancer cells and cause mutations in our own genomic DNA. These mutations fuel tumor evolution and promote poor clinical outcomes such as drug resistance and metastasis."

With an imaging technique called x-ray crystallography, which uses a high energy x-ray beam to visualize the atomic details of molecules, researchers were able to see an unexpected mode of DNA binding activity. A unique U-shaped DNA conformation and defined pockets for the target cytosine and the adjacent thymine base explains the specific mutation signature left behind by the enzyme interacting with tumor DNA.

"Our crystal structures and corroborating biochemical experiments show how APOBEC3A and APOBEC3B engage DNA substrates," said Hideki Aihara, Ph.D., associate professor in the department of Biochemistry, Molecular Biology and Biophysics and member of the Institute of Molecular Virology and the Masonic Cancer Center at the University of Minnesota. "These structures show an unexpected mode of DNA engagement with a sharply bent DNA strand and flipped-out nucleotides. Our findings were surprising, but actually make a lot of sense and explain many previous observations about this family of proteins."

The DNA-binding mechanism suggests ways to block enzyme activity in cancer, which could slow the rate at which tumors evolve. Inhibiting APOBEC activity could make current anti- therapies more effective.

Work continues to take and analyze additional portraits of these enzymes with different DNA substrates and to devise strategies for inhibition.

Explore further: Antiviral enzyme contributes to several forms of cancer

More information: Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B, Nature Structural and Molecular Biology, nature.com/articles/doi:10.1038/nsmb.3344

Related Stories

Antiviral enzyme contributes to several forms of cancer

July 14, 2013
Researchers at the University of Minnesota have discovered that a human antiviral enzyme causes DNA mutations that lead to several forms of cancer.

Culprit found in breast cancer resistance to tamoxifen

October 7, 2016
Researchers have discovered that a protein found naturally in cells that provides some protection from viruses is responsible for creating mutations that drive resistance to tamoxifen treatment in breast cancer. Because the ...

Researchers discover enzyme behind breast cancer mutations

February 6, 2013
Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme – called APOBEC3B – may change the way ...

An unexpected role for epigenetic enzymes in cancer

December 6, 2016
To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the ...

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

December 10, 2015
Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by increasing levels of APOBEC3B, ...

Scientists discover new cancer connection

December 14, 2016
A biologist at The University of Texas at Dallas and his colleagues have discovered that two enzymes previously linked independently with keeping cancer cells alive actually work in tandem to spur tumor growth.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.